Glancy Prongay & Murray LLP Announces Investigation of Blue Bird Corporation (BLBD) (f/k/a Hennessy Capital Acquisition Corp.)
Glancy Prongay & Murray LLP Announces Investigation of Blue Bird Corporation (BLBD) (f/k/a Hennessy Capital Acquisition Corp.)
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Blue Bird Corporation (Nasdaq: BLBD) (f/k/a Hennessy Capital Acquisition Corp.) concerning the Company and its directors’ and officers’ possible violations of state laws.
If you own Blue Bird stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy@glancylaw.com, or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP
Tom Kennedy, 212-682-5340
tkennedy@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202186991/en/
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year